Synonyms[]
Antibodies[]
Technical Info[]
Staining Pattern[]
Endoplasmic reticulum, nuclear envelope, and inner mitochondrial membrane.
Expression in Normal Tissues[]
- Lymphocytes in mantle zone and T cell areas of lymph nodes
Expression in Neoplastic Entities[]
Benign[]
| Tumor name | % Positive Staining | Number of Cases |
| Solitary Fibrous Tumor (Hemangiopericytoma) | 100%[1] | 16/16[1] |
| Cellular Blue Nevus[2] | ||
Intermediate/Uncertain Malignant Potential[]
| Tumor name | % Positive Staining | Number of Cases |
Malignant[]
| Tumor name | % Positive Staining | Number of Cases |
| Synovial Sarcoma (including monophasic [MFSS] and poorly differentiated[PDSS])[3] | MFSS 91%, PDSS 92%[3] | MFSS 43/47, PDSS 12/13[3] |
| Follicular Lymphoma (Grade I, Grade II, Grade III) | 97%, 83%, 74%[4] | 107/110, 119/143, 71/96[4] |
| Clear cell sarcoma | 94%[5] | 30/32[5] |
Expression in Non-Neoplastic Entities[]
Pertinent Negatives[]
This antigen is typically NOT expressed by the following entities:
Practical Uses / Panels[]
- Follicular Lymphoma (positive germinal centers) vs. follicular/reactive hyperplasia (negative germinal centers)
Common Pitfalls[]
BCL-2 expression decreases with increasing grade in Follicular Lymphoma.
Laboratory Investigation (2004) 84, 235–244, advance online publication, 19 January 2004; doi:10.1038/labinvest.3700051